Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Dexamethasone dose intensity does not improve 6-month responses in newly diagnosed multiple myeloma and may contribute to hyperglycemia

Gui Zhen Chen, Jenna Voutsinas, Qian Wu, Xiang Yu Gao, Ayushi Gupta, Rahul Banerjee, Andrew Cowan

Blood (2025) 146 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2025-2207

Published: 2025

Journal Articles

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Lorenzo Iovino, Ningxin Ma, Mohamed Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani, Peter Riedell, Ajay Gopal, Leona Holmberg, Qian Wu, Sonali Smith, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2025-5483

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Mengyang Di, Scott Huntington, Jenna Voutsinas, Qian Wu, Scott Ramsey, Jennifer Huang, Ajay Gopal, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2025-4520

Published: 2025

Journal Articles

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Mengyang Di, Qian Wu, Ryan Lynch, Stephen Smith, Mazyar Shadman, Paul Martin, Brian Till, Neena Kennedy, Chaitra Ujjani, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2025-5394

Published: 2025

Journal Articles

Next generation sequencing from dried blood spots: “Spot on CML” results from low- and middle-income countries

Vivian Oehler, Olga Sala-Torra, Neta Gilderman, Lan Beppu, David Woolston, Priscilla Namaganda, Jennifer Rynning, Ines Garcia Gonzalez, Andrea Towlerton, Jenna Voutsinas, Qian Wu, Cecilia Yeung, Jerald Radich

Blood (2025) 146 (Supplement 1): 5559.

https://doi.org/10.1182/blood-2025-5559

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel

Yein Jeon, Xiancheng Wu, Christy Khouderchah, Emily Liang, Andrew Portuguese, Jennifer Huang, Erik Kimble, Alexandre Hirayama, Mazyar Shadman, Andrew Cowan, Danai Dima, Rahul Banerjee, Madhav Dhodapkar, Lawrence Fong, Qian Wu, Meredith Durbin, Jordan Gauthier

Blood (2025) 146 (Supplement 1): 4147.

https://doi.org/10.1182/blood-2025-4147

Published: 2025

Journal Articles

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

Rong Xie, Qiang He, Linna Xie, Lili Feng, Qi Kong, Kuntong Liu, Ziqing Ma, Yuhong Ba, Zonghong Li, Qian Wu, Tan Sang, Y. Lynn Wang, Ji Ma

Blood (2025) 146 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2025-7221

Published: 2025

Journal Articles

Real-world barriers to treatment access in T-cell lymphoma

Bryce Bowler, Jenna Voutsinas, Qian Wu, Maya Krishnan, Dhruv Mistry, Grace Sun, Mazyar Shadman, Brian Till, Ryan Lynch, Vikram Raghunathan, Chaitra Ujjani, Stephen Smith, Mengyang Di, Paul Martin, Ajay Gopal, Christina Poh

Blood (2025) 146 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2025-4491

Published: 2025

Journal Articles

Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL

Colleen Annesley, Kristy Seidel, Qian Wu, Corinne Summers, Alan S. Wayne, Michael A. Pulsipher, Anurag K. Agrawal, Chris T. Brown, Stephanie Mgebroff, Catherine Lindgren, Stephanie Rawlings-Rhea, Wenjun Huang, Ashley L. Wilson, Michael C. Jensen, Julie R. Park, Rebecca A. Gardner

Blood (2025) 146 (7): 789–801.

https://doi.org/10.1182/blood.2025028359

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Ji Ma, Qiang He, Qian Wu, Lili Feng, Y. Lynn Wang, Linna Xie

Blood (2024) 144 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2024-204227

Published: 2024

Journal Articles

Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus

Qian Wu, Dong Chen

Blood (2024) 144 (17): 1846.

https://doi.org/10.1182/blood.2024026443

Published: 2024

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Carrie I Ho, Ajay K Gopal, Chaitra S Ujjani, Ryan C Lynch, Christina Poh, Jenna M Voutsinas, Qian Wu, Jacquelin Vandermeer, Jonathan R Fromm, Stephen D Smith

Blood (2023) 142 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2023-177682

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma

George Mo, Sang Yun Lee, Jenna M Voutsinas, Qian Wu, Dong Hoon Lee, Jordan Gauthier, Alexandre V Hirayama, David G Maloney, Mazyar Shadman, Brian G Till

Blood (2023) 142 (Supplement 1): 6877.

https://doi.org/10.1182/blood-2023-180446

Published: 2023

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Christina Poh, Ryan C Lynch, Edus H Warren, Chaitra S Ujjani, Stephen D Smith, Michi M Shinohara, Jonathan R Fromm, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Laura Naylor, Heather Rasmussen, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2023-178279

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dexamethasone dose intensity does not improve 6-month responses in newly diagnosed multiple myeloma and may contribute to hyperglycemia

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Next generation sequencing from dried blood spots: “Spot on CML” results from low- and middle-income countries

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

Real-world barriers to treatment access in T-cell lymphoma

Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only